Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-10-01-2001
Volume0
Issue 0

Illegal Sales in India

Author(s):

Kevin Gopal

Mumbai, India—The controversy over pharma companies’ incentives to pharmacists in India highlights just how competitive the Indian pharma industry has become.

Articles in this issue
National Crisis Supercedes Coverage Debate
PBMs: Merck-Medco in the Hot Seat
National Crisis Supercedes Coverage Debate
image4-686-1409031567502.gif
A Five-Year Forecast: Clear Seas Ahead?
Weak Bones, Strong Market
Weak Bones, Strong Market
Approvals: Novartis’ Silver Lining

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Pharmaceutical Executive
Helen Sabzevari
Pharmaceutical Executive
Related Content
Dan Wolff
September 12th 2025

How Pharmaceutical Manufacturers Are Overcoming Supply Chain and Compliance Pressures

Dan Wolff
Pharmaceutical Executive
September 12th 2025

Pharmaceutical Executive Daily: September 11, 2025

Nicholas Jacobus
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
September 12th 2025

FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration

Don Tracy, Associate Editor
Pharmaceutical Executive
September 12th 2025

Pharmaceutical Executive Daily: September 9, 2025

Nicholas Jacobus
Stock.adobe.com
September 12th 2025

Merck Discards New Research Center in Britain Amongst Turmoil in Pharmaceutical Industry Investments

Nicholas Jacobus
Pharm Exec MFN webinar
September 12th 2025

What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients

Mike Hollan
© 2025 MJH Life Sciences

All rights reserved.